Related Experiment Video
Updated: May 3, 2026

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model
Published on: July 2, 2016
Passive immunization against HIV/AIDS by antibody gene transfer
1Department of Microbiology, Immunology and Molecular Genetics, Eli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California at Los Angeles, Los Angeles, CA 90095, USA. liliyang@ucla.edu.
Vectored ImmunoProphylaxis (VIP) offers a novel passive immunization strategy for HIV. This approach uses viral vectors to deliver genes for broadly neutralizing antibodies (bnAbs), showing robust protection in preclinical models.
Area of Science:
- Immunology
- Virology
- Gene Therapy
Background:
- The development of an effective HIV vaccine via active immunization has faced significant challenges.
- Passive immunization strategies are being explored as an alternative to traditional vaccines.
- Broadly neutralizing antibodies (bnAbs) show promise in preventing HIV infection.
Purpose of the Study:
- To review the progress and potential of Vectored ImmunoProphylaxis (VIP) for HIV prevention.
- To detail preclinical studies of VIP in animal models.
- To discuss the clinical applicability of VIP for controlling HIV/AIDS.
Main Methods:
- Viral vector-mediated delivery of genes encoding bnAbs for in vivo expression.
- Preclinical studies in humanized mice and macaque monkeys.
- Evaluation of protection against HIV and related viral infections.
Main Results:
- VIP demonstrated robust protection against virus infection in preclinical settings.
- Successful in vivo expression of monoclonal neutralizing antibodies was achieved.
- VIP represents a promising new strategy for HIV prevention.
Conclusions:
- Vectored ImmunoProphylaxis (VIP) presents a novel and promising approach to HIV prevention.
- Further research and clinical trials are needed to assess the full potential of VIP.
- VIP could offer a new avenue for controlling the global HIV/AIDS pandemic.
More Related Videos
09:20Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants
Published on: October 18, 2022
12:03Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
Related Concept Videos
Gene Therapy
Active versus Passive Immunity
Active Immunity
Active immunity refers to the resistance one develops...
Types of Genetic Transfer Between Organisms
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Horizontal Gene Transfer